Global Neuroendocrine Tumors Therapeutics Market 2019-2023
SKU ID : TNV-14141992 | Publishing Date : 10-Apr-2019 | No. of pages : 129
Detailed TOC of Global Neuroendocrine Tumors Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Somatostatin analogs - Market size and forecast 2018-2023
Targeted therapies - Market size and forecast 2018-2023
Other therapies - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
F. Hoffmann-La Roche Ltd
Ipsen Pharma
Merck & Co., Inc
Novartis AG
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Somatostatin analogs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Somatostatin analogs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Targeted therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapies - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other therapies - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other therapies - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Strategic alliances in global neuroendocrine tumors therapeutics market: Overview
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 56: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 57: Ipsen Pharma - Vendor overview
Exhibit 58: Ipsen Pharma - Business segments
Exhibit 59: Ipsen Pharma - Organizational developments
Exhibit 60: Ipsen Pharma - Geographic focus
Exhibit 61: Ipsen Pharma - Segment focus
Exhibit 62: Ipsen Pharma - Key offerings
Exhibit 63: Ipsen Pharma - Key customers
Exhibit 64: Merck & Co., Inc - Vendor overview
Exhibit 65: Merck & Co., Inc - Business segments
Exhibit 66: Merck & Co., Inc - Organizational developments
Exhibit 67: Merck & Co., Inc - Geographic focus
Exhibit 68: Merck & Co., Inc - Segment focus
Exhibit 69: Merck & Co., Inc - Key offerings
Exhibit 70: Merck & Co., Inc - Key customers
Exhibit 71: Novartis AG - Vendor overview
Exhibit 72: Novartis AG - Business segments
Exhibit 73: Novartis AG - Organizational developments
Exhibit 74: Novartis AG - Geographic focus
Exhibit 75: Novartis AG - Segment focus
Exhibit 76: Novartis AG - Key offerings
Exhibit 77: Novartis AG - Key customers
Exhibit 78: Pfizer Inc. - Vendor overview
Exhibit 79: Pfizer Inc. - Business segments
Exhibit 80: Pfizer Inc. - Organizational developments
Exhibit 81: Pfizer Inc. - Geographic focus
Exhibit 82: Pfizer Inc. - Segment focus
Exhibit 83: Pfizer Inc. - Key offerings
Exhibit 84: Pfizer Inc. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Keyplayers in Global Neuroendocrine Tumors Therapeutics Market 2019-2023
F. Hoffmann-La Roche LtdIpsen Pharma
Merck & Co., Inc
Novartis AG
Pfizer Inc.